Acute-to-chronic Glycemic Ratio (ACGR) is a Marker of DFUs .

NCT06725238 | Completed

• 2 other identifiers: PH130-24University of Sulaimani
• Study Type: observational
• Target: 80
• Locations: 1 country
• Sites: 1

Brief Summary

Diabetic foot ulcers (DFUs) have resulted from peripheral arterial ischemia and peripheral neuropathy that are complicated with infections and amputation of the lower extremities. Uncontrolled glycemic status and significantly higher glycosylated hemoglobin (HbA1c) are associated with DFUs. This study aimed to assess the acute-to-chronic glycemic ratio (ACGR) in type 2 diabetes (T2D) with DFUs and compare it with those without DFUs, considering the relationships of this ratio with other indices that characterized the pathogenesis of T2D. This cross-sectional study was conducted on T2D with DFUs and non-DFUs. The primary outcome is ACGR. The secondary outcomes are indices related to the anthropometric, metabolic, and hematological variables.

Conditions

Diabetic Foot Ulcer (DFU)

Keywords

Diabetes foot ulcers; Acute-to-chronic glycemic index; Leucocyte-glucose index; Triglyceride-glucose index

Outcome Measures

Primary Outcomes (1)

• Acute-to-chronic glycemic ratio

  The glycemic index represents the current or acute level of fasting plasma glucose and the HbA1c, which indicates the chronic glycemic status, is elevated in DFUs. The chronic plasma glucose level could be determined by using the equation of 28.7 × HbA1c (%) - 46.7.

  The measurement is done at the time of recruitment

Secondary Outcomes (1)

• Leucocyte-glucose index

  at the time of recruitment

Study Arms (2)

Group I : patients presented with DFUs.

Participants who were referred to the consultant clinics at the Shar hospital were included if they had (i) a history of T2D irrespective of antidiabetic medicines or (ii) clinical and laboratory evidence of diabetic foot ulcers.

Other: Acute-to-chronic glycemic ratio

Group II: patients who had T2D without DFUs

The participants have no previous history of diabetic foot ulcer or amputation. There were managed with oral anti-diabetes or occasionally with short term insulin therapy

Interventions

Acute-to-chronic glycemic ratio OTHER

This ratio could be related to diabetic foot ulcer

Also known as: Leucocyte glucose index, Triglyceride-glucose index

Group I : patients presented with DFUs.

Eligibility Criteria

• Age: 18 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Diabetic participants with or without diabetic foot ulcer who were referred to the consultant clinics at the Shar hospital in Sulaymaniyah, Iraq were recruited

You may qualify if:

• Type 2 Diabetes Clinical and laboratory diagnosis of diabetic foot ulcers Treatment with oral anti-diabetes +/- insulin

You may not qualify if:

• History of recent systemic infections Alcohol consumption Surgical procedures within 4 weeks Pregnant or breast-feeding women; Terminal illnesses.

Sponsors & Collaborators

• University of Diyala: lead

Study Sites (1)

College of Medicine, University of Diyala

Baqubah, Diyala Governorate, 32001, Iraq

Location

Related Publications (1)

• Armstrong DG, Tan TW, Boulton AJM, Bus SA. Diabetic Foot Ulcers: A Review. JAMA. 2023 Jul 3;330(1):62-75. doi: 10.1001/jama.2023.10578.

  PMID: 37395769 BACKGROUND

Related Links

• An article was studied the benefit of determination the stress hyperglycemia

MeSH Terms

Conditions

Diabetic Foot

Condition Hierarchy (Ancestors)

Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Foot Ulcer; Leg Ulcer; Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Diabetic Neuropathies

Study Officials

• Rawa A Ratha, M.Sc., PhD

  College of Pharmacy, University of Sulaimani, Sulaymaniyah

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Target Duration: 7 Days
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Clinical Pharmacology and Therapeutics

Study Record Dates

• First Submitted: December 4, 2024
• First Posted: December 10, 2024
• Study Start: May 1, 2024
• Primary Completion: November 1, 2024
• Study Completion: November 10, 2024
• Last Updated: December 10, 2024

Record last verified: 2024-12

Data Sharing

• IPD Sharing: Will not share

Locations

IR (1)